Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
Paul McKenzie, CEO & Managing Director at CSL, shared a post on LinkedIn:
“Bleeding Disorders Awareness Month is a time to honor the resilience of those living with inherited bleeding disorders.
At CSL, we take pride in our history of pioneering advancements in the treatment and management of these lifelong, chronic diseases, as well as in our dedication to supporting patients and their caregivers.
In recent years, significant advancements in treatment, including gene therapies, have emerged with the potential to significantly improve the lives of individuals with hemophilia.
We commend the researchers, clinicians, and advocates who have contributed to these important developments.
Gene therapy offers a transformative approach for hemophilia patients by enabling them to produce their own clotting factor, potentially reducing bleeds and eliminating the need for ongoing treatments.
These one-time infusions address the genetic cause of hemophilia and potentially provide improved bleed protection, which can lead to less anxiety and an enhanced quality of life.
See here for the latest news on gene therapy in hemophilia.
We are proud to have brought the first approved gene therapy to people with hemophilia B. Over the past two years, CSL has made progress in expanding access to this therapy in the US and Europe.
This has only been possible through our strong collaboration with patients, national authorities, clinicians, patient advocates and payers.
There is still much work to be done.
We will continue to educate health systems on the value of gene therapy drive innovative access solutions, enable patient identification and education and create new clinical pathways.
We are dedicated to collaborating with community partners to enhance the accessibility of gene therapy for individuals with hemophilia.
Our goal is to provide a wider range of treatment options that address the diverse needs of this population.
For over 50 years, CSL has developed treatments for bleeding disorders and other rare diseases, with input and support from the patient community.
We are committed to innovative solutions that make a lasting impact on the lives of the patients we serve.
Our unwavering support for our patients and the communities that advocate for and treat them remains steadfast.
We stand by you every step of the way.”
Stay updated with Hemostasis Today.
-
May 31, 2026, 13:16Caroline Kisia: Project ECHO Transforms Healthcare Around The World
-
May 31, 2026, 13:11Wolfgang Miesbach: From CD20 to CD38 – A New Dimension in ITTP Therapy
-
May 31, 2026, 13:05Ellia Tootoonchian: Advancing Equitable Care Through Global Collaboration at WFH 2026
-
May 31, 2026, 12:55Rishiraj Sinha: Transfusion Evidence Library Round-Up – International Thalassaemia Day 2026
-
May 31, 2026, 12:40Tareq Abadl: Key Differences Between Immune Thrombocytopenic Purpura and Thrombotic Thrombocytopenic Purpura
-
May 31, 2026, 12:37Jeyaraj Pandian: World Stroke Organization Advances Stroke Education and Care in Central Asia
-
May 31, 2026, 12:31Stephen James Ryan: We Validated the Norwegian Version of the Vision Impairment Screening Assessment in Stroke
-
May 31, 2026, 12:01Sheila Cristina Ouriques Martins: We Provide Practical, Real-World Examples on How to Implement Stroke Prevention Strategies
-
May 31, 2026, 11:51Seema Dawood: Principles of Blood Smear Examination and Interpretation